Probiotics That Support Mental Health and Stress Resilience

How specific probiotic strains modulate the gut-brain axis to reduce anxiety, improve stress responses, and support mood — with evidence from human clinical trials

Psychobiotics are specific probiotic strains — and sometimes prebiotic fibers — that demonstrably benefit mental health by communicating with the brain through the gut-brain axis [1]. Research has identified several strains, particularly among Bifidobacterium and Lactobacillus species, that reduce perceived stress, lower anxiety scores, and improve mood in human clinical trials [2][5]. They work through multiple pathways: producing neurotransmitter precursors, modulating the vagus nerve, lowering inflammatory cytokines, and regulating the hypothalamic-pituitary-adrenal (HPA) axis — the same stress-response system that antidepressants often target [1]. This is not a replacement for mental health care, but for people dealing with stress, mild anxiety, or poor sleep, targeted probiotic strains represent a well-tolerated, evidence-based tool worth knowing about.

The Gut-Brain Axis — How Your Microbiome Talks to Your Mind

The gut and brain maintain a continuous two-way dialogue. The vagus nerve — a long cranial nerve running from the brainstem to the abdomen — carries signals in both directions, and the gut itself contains about 100 million neurons, sometimes called the enteric nervous system or "second brain." Gut bacteria influence this system in several ways:

Neurotransmitter production: Gut bacteria synthesize or stimulate production of GABA, serotonin, dopamine precursors, and acetylcholine. Roughly 90% of the body's serotonin is produced in the gut, where it regulates motility — but the bacteria influencing serotonin production also affect mood-related signaling.
Short-chain fatty acids: Fermentation of dietary fiber by gut bacteria yields butyrate and propionate, which cross the blood-brain barrier and reduce neuroinflammation.
HPA axis regulation: A dysbiotic microbiome is associated with elevated cortisol output and a hyperactivated stress response. Certain probiotic strains normalize this, reducing basal cortisol and dampening the cortisol spike after acute stress [2].
Immune signaling: Bacteria regulate the production of pro-inflammatory cytokines like IL-6 and TNF-α, which when chronically elevated are associated with depression. By reducing systemic inflammation, psychobiotics may remove one driver of low mood.

The term "psychobiotic" was formally coined in 2013 by Dinan, Stanton, and Cryan to describe live organisms that, when ingested in adequate amounts, produce a health benefit in patients suffering from psychiatric illness — specifically through the gut-brain axis [1].

Which Strains Have the Best Evidence?

Not all probiotics affect the brain. Most standard probiotic supplements contain strains chosen for gut health, not mental health. The evidence is strain-specific:

Bifidobacterium longum 1714™ is the most thoroughly studied psychobiotic strain in human trials. In a double-blind, crossover RCT, healthy volunteers who took B. longum 1714 for four weeks showed reduced subjective anxiety and improved memory performance on a sustained attention task compared to placebo [2]. A follow-up trial found that the strain modulated resting EEG theta wave activity — a neural signature associated with relaxed alertness — and altered brain responses during a standardized social stress task [3]. This strain appears to work partly by dampening the HPA axis response to stress.

Lactobacillus plantarum PS128 has been studied for depression and sleep quality in insomniacs. A placebo-controlled pilot trial found significant reductions in Beck Depression Inventory (BDI-II) scores and improved sleep efficiency compared to controls after four weeks [4]. The strain is notable for producing GABA and for crossing preclinical to clinical research with consistent effects on dopamine and serotonin pathways.

Lactobacillus rhamnosus strains — particularly JB-1 — have been extensively studied in animal models, where they reliably reduce anxiety behavior and cortisol through vagal signaling. Human evidence is more limited but promising, particularly for stress-related gut symptoms and mild anxiety.

Multi-strain combinations show moderate effects as a class. A 2025 meta-analysis of 23 RCTs (1,401 participants) found that probiotic use for up to 8 weeks produced significant reductions in both depressive and anxiety symptoms in clinically diagnosed populations — though single-strain preparations showed slightly stronger effects than multi-strain blends, likely because strain interactions are poorly understood [5].

Practical Considerations

Dosing and duration: Most clinical trials used doses of 1–10 billion CFU per day for 4–8 weeks. Effects tend to emerge gradually — most studies show measurable changes by weeks 4–6, with sustained benefits at 8 weeks.

Who may benefit most: Psychobiotics appear most effective in people with existing mild-to-moderate stress, anxiety, or disrupted sleep. Effects in people with severe clinical depression are more modest and should not be considered a stand-alone treatment.

Diet matters: Psychobiotics don't act in isolation. A fiber-rich diet feeds the strains and supports production of SCFAs that amplify their effects. Ultra-processed foods and alcohol can shift the microbiome in directions that undermine psychobiotic benefit within days.

Prebiotic pairing: Some trials have combined specific probiotic strains with prebiotic fibers (galactooligosaccharides or fructooligosaccharides) that selectively feed them. This synbiotic approach tends to show more durable colonization, though direct head-to-head comparisons with probiotic-only groups remain limited.

See our Gut-Brain Axis page for the broader science on how your microbiome influences mood, cognition, and neurological health. The Probiotics page covers strain selection for gut-specific benefits.

Evidence Review

Coining the Concept (Dinan et al., 2013)

The foundational 2013 paper in Biological Psychiatry by Timothy Dinan, Catherine Stanton, and John Cryan established the psychobiotic framework [1]. The authors proposed a formal definition — live organisms that, when consumed in adequate amounts, produce a mental health benefit in clinically ill patients — and outlined the mechanistic pathways through which gut bacteria could plausibly affect the brain. The paper synthesized then-available animal research (primarily in germ-free and gnotobiotic mouse models) showing that gut bacteria alter GABA receptor expression throughout the cortex and limbic system, regulate HPA axis reactivity to stress, and modulate vagal afferent signaling. Critically, the authors noted that the effects were strain-specific: not all Lactobacillus strains affect anxiety, just as not all antidepressants affect the same neurotransmitter. This conceptual framework has since been validated in human trials and has guided the design of strain-specific clinical research. The paper also proposed that prebiotics capable of selectively enriching psychoactive microbial populations should be considered psychobiotics as well — a category now sometimes called "prebiotics with psychotropic potential."

B. longum 1714 — Stress and Cognition RCT (Allen et al., 2016)

This double-blind, placebo-controlled, crossover trial enrolled 22 healthy male volunteers and assessed the effects of Bifidobacterium longum 1714 (10⁹ CFU/day) over two 4-week periods separated by a 4-week washout [2]. The primary endpoints were subjective stress (measured via the Perceived Stress Scale), cognitive performance (sustained attention, visuospatial learning, and memory), and HPA axis reactivity (cortisol output during a cold pressor test).

Key results: Daily stress scores were significantly lower during the B. longum 1714 condition versus placebo (p = 0.031). The cold pressor test — a standardized laboratory stressor — elicited a blunted cortisol response during the probiotic phase, suggesting HPA axis downregulation. Cognitive testing revealed improved spatial working memory performance on the Cambridge Neuropsychological Test Automated Battery (CANTAB) during the probiotic condition. EEG recordings showed a significant reduction in frontal theta wave power, a neural signature previously associated with emotional engagement and anxiety. The authors concluded that B. longum 1714 functions as a genuine psychobiotic in healthy adults — reducing both the subjective experience of stress and the measurable physiological stress response, while improving specific aspects of cognition. This remains one of the most methodologically rigorous psychobiotic trials in healthy populations.

B. longum 1714 — Social Stress Neural Modulation (Wang et al., 2019)

This randomized, double-blind, placebo-controlled trial from the University of Tübingen enrolled 40 healthy volunteers who received either Bifidobacterium longum 1714 (10⁹ CFU/day) or placebo for 4 weeks [3]. The study used a well-validated social exclusion paradigm (the "Cyberball" task) while participants underwent functional neuroimaging and continuous EEG to capture real-time brain responses to social rejection.

During the social stress task, participants taking B. longum 1714 showed significantly different neural activation patterns compared to placebo — specifically, altered activity in regions associated with emotional regulation, including the anterior cingulate cortex and prefrontal areas involved in cognitive reappraisal of threat. The probiotic group also reported higher scores on a vitality subscale and lower scores on mental fatigue at the end of the intervention (p < 0.05 for both). The EEG data corroborated the neuroimaging findings: resting theta power was modified in a direction consistent with less anxious baseline neural states. The authors interpreted these findings as evidence that B. longum 1714 modulates the neural circuitry involved in processing social stressors — helping the brain shift from a threat-reactive state toward more adaptive coping responses. This study is notable for combining subjective self-report measures with objective neuroimaging, providing converging evidence at multiple levels of analysis.

L. plantarum PS128 for Depression and Sleep (Ho et al., 2021)

This randomized, double-blind, placebo-controlled pilot trial tested Lactobacillus plantarum PS128 (60 billion CFU/day, administered as two divided doses) in 30 adults self-reporting insomnia [4]. The intervention lasted 4 weeks, with assessments at baseline, 2 weeks, and 4 weeks. Primary outcomes included the Beck Depression Inventory-II (BDI-II), the Pittsburgh Sleep Quality Index (PSQI), the Epworth Sleepiness Scale, and polysomnographic sleep recording.

After 4 weeks, the PS128 group showed a statistically significant reduction in BDI-II depression scores compared to placebo (within-group p < 0.001; between-group p = 0.041). Objective sleep monitoring showed improved sleep efficiency (time asleep as a percentage of time in bed) and reduced wake-after-sleep-onset in the probiotic group. Autonomic nervous system analysis using heart rate variability data suggested increased parasympathetic tone — indicating a shift away from sympathetic arousal — in the PS128 group compared to placebo. The mechanism proposed by the authors centers on PS128's known capacity to produce GABA and to upregulate tryptophan hydroxylase-2 in the gut, increasing serotonin precursor availability. Limitations include the small sample size and pilot design; the authors called for larger confirmatory trials. Nonetheless, the concurrent improvement in both mood and sleep architecture — two domains that typically reinforce each other — makes PS128 a plausible candidate for further clinical development.

Meta-Analysis of RCTs in Clinically Diagnosed Populations (Asad et al., 2025)

This systematic review and meta-analysis, published in Nutrition Reviews, pooled data from 23 randomized controlled trials involving 1,401 participants with clinically diagnosed depression or anxiety disorders [5]. Trials were included only if participants had a formal diagnosis (not just subclinical stress), used validated psychiatric rating scales as outcomes, and had a placebo comparator. The primary outcome was standardized mean difference (SMD) in depression or anxiety scale scores between probiotic/prebiotic and placebo groups at end of intervention.

The meta-analysis found a statistically significant reduction in depression symptoms (SMD = −0.51, 95% CI: −0.74 to −0.28, p < 0.001) and anxiety symptoms (SMD = −0.43, 95% CI: −0.67 to −0.20, p < 0.001) in the probiotic/prebiotic group relative to placebo. Importantly, single-strain probiotic interventions showed slightly larger effect sizes than multi-strain preparations, though the difference was not statistically significant. Intervention duration ranged from 4 to 24 weeks, with the majority of benefit observed within the first 8 weeks. Subgroup analysis found that Lactobacillus-containing preparations had a stronger effect on anxiety, while Bifidobacterium-containing preparations tended to show greater effect on depressive symptoms. The authors noted significant heterogeneity across trials (I² = 62%), reflecting differences in strain type, dose, and diagnostic criteria — limiting the generalizability of specific dosing recommendations. The review authors concluded that the current evidence supports probiotic supplementation as a safe adjunctive strategy for depression and anxiety, while emphasizing that it should not replace established pharmacological or psychotherapeutic treatments.

References

Psychobiotics: a novel class of psychotropicDinan TG, Stanton C, Cryan JF. Biological Psychiatry, 2013. PubMed 23759244 →
Bifidobacterium longum 1714 as a translational psychobiotic: modulation of stress, electrophysiology and neurocognition in healthy volunteersAllen AP, Hutch W, Borre YE, Kennedy PJ, Temko A, Boylan G, Murphy E, Cryan JF, Dinan TG, Clarke G. Translational Psychiatry, 2016. PubMed 27801892 →
Bifidobacterium longum 1714™ Strain Modulates Brain Activity of Healthy Volunteers During Social StressWang H, Braun C, Murphy EF, Enck P. American Journal of Gastroenterology, 2019. PubMed 30998517 →
Effects of Lactobacillus plantarum PS128 on Depressive Symptoms and Sleep Quality in Self-Reported Insomniacs: A Randomized, Double-Blind, Placebo-Controlled Pilot TrialHo YT, Tsai YC, Kuo TBJ, Yang CCH. Nutrients, 2021. PubMed 34444980 →
Effects of Prebiotics and Probiotics on Symptoms of Depression and Anxiety in Clinically Diagnosed Samples: Systematic Review and Meta-analysis of Randomized Controlled TrialsAsad A, Kirk M, Zhu S, Dong X, Gao M. Nutrition Reviews, 2025. PubMed 39731509 →